Bausch + Lomb Corporation

https://www.bausch.com

Bausch + Lomb Corporation is a global eye health company dedicated to helping people see better to live better. Founded in 1853, it stands as one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company's corporate headquarters are located in Vaughan, Ontario, Canada, with a significant U.S. headquarters in Bridgewater, New Jersey.

Bausch + Lomb operates through three primary segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment offers a wide range of contact lenses, lens care products, and over-the-counter eye health products such as eye drops and vitamins, including brands like Biotrue, PreserVision, and Lumify. Its Pharmaceuticals segment provides proprietary and generic treatments for various eye conditions, including glaucoma, dry eyes, and post-operative care, with products like XIIDRA and Vyzulta. The Surgical segment focuses on medical device equipment, consumables, and technologies for cataract, corneal, vitreous, and retinal eye conditions, featuring intraocular lenses and advanced surgical systems.

Led by CEO and Chairman Brent Saunders, Bausch + Lomb maintains a leading position in the eye care industry, competing with major players globally. The company recently reported strong first-quarter 2026 financial results, with revenue reaching $1.244 billion, an increase of 9% year-over-year, and subsequently raised its full-year 2026 revenue guidance. Bausch + Lomb continues to invest in innovation, with plans for new daily disposable silicone hydrogel multifocal and toric contact lenses in 2026, and has recently launched the enVista Envy full range of vision intraocular lens in Europe. The company is a subsidiary of Bausch Health Companies Inc., which holds an 88% ownership stake.

Latest updates

Bausch + Lomb Showcases Pipeline Data at ARVO Meeting

Event summary

  • Bausch + Lomb will present over 40 scientific studies at the 2026 ARVO Annual Meeting in Denver, May 3-7.
  • Data will be showcased for existing products including LUMIFY, Blink NutriTears, XIIDRA, MIEBO, Biotrue contact lenses, and enVista IOLs.
  • New data will be presented on pipeline assets including enVista Beyond lens and candidates for glaucoma, neuropathic pain, AMD, and lens care.
  • The presentations include Phase 2 trial data for BL1107, a treatment for glaucoma.

The big picture

Bausch + Lomb's commitment to showcasing extensive clinical data at ARVO underscores its focus on scientific validation and market differentiation within the competitive eye health sector. The breadth of studies, spanning from dry eye treatments to advanced IOLs and pipeline candidates, signals a continued investment in innovation. This public display of data is a strategic move to build credibility and potentially influence prescribing patterns among ophthalmologists.

What we're watching

Pipeline Progress
The success of Bausch + Lomb’s pipeline candidates, particularly those targeting glaucoma, AMD, and neuropathic pain, will be crucial for long-term growth and will be assessed by the reception of the presented data.
Clinical Adoption
The adoption rate of newer products like MIEBO and enVista Beyond will depend on the clinical data presented and physician feedback, which could impact revenue projections.
Competitive Landscape
The data presented will be scrutinized by competitors to identify potential vulnerabilities in Bausch + Lomb’s product portfolio and inform their own R&D strategies.

Bausch + Lomb Raises Guidance on Strong Q1, Margin Expansion

Event summary

  • Bausch + Lomb reported first-quarter 2026 revenue of $1.244 billion, up 9% year-over-year.
  • Pharmaceuticals segment revenue grew by 14%, driven by MIEBO (+33%) and XIIDRA (+30%).
  • The company raised its full-year 2026 revenue guidance from $5.375B - $5.475B to $5.420B - $5.520B.
  • Operating income improved significantly to $33 million, compared to an $83 million operating loss in Q1 2025.

The big picture

Bausch + Lomb's strong Q1 results and revised guidance signal a successful turnaround strategy under Brent Saunders, demonstrating a focus on margin expansion and operational improvements. The company's reliance on acquisitions like MIEBO and XIIDRA highlights a growth-through-acquisition strategy common in the fragmented eye health market. The increased guidance suggests a more optimistic outlook for the broader eye care sector, though execution risks remain.

What we're watching

Growth Sustainability
Whether Bausch + Lomb can sustain the double-digit growth in its Pharmaceuticals segment, particularly given the reliance on MIEBO and XIIDRA, will be a key indicator of long-term performance.
AI Integration
The effectiveness of Bausch + Lomb's broad AI adoption in driving operational efficiencies and offsetting inflationary pressures warrants close monitoring.
Regulatory Landscape
The pace at which LUMIFY NXT and seeLYRA gain market share following regulatory approvals will influence the company’s ability to meet revised guidance.

Bausch + Lomb Bolsters Eye Health Portfolio with B Vitamin Research

Event summary

  • A narrative review published in *Ophthalmology and Therapy* highlights the potential of B vitamins in reducing the risk and progression of Age-Related Macular Degeneration (AMD).
  • The review synthesizes data from over 20 human studies involving nearly 30,000 individuals, spanning two decades of research.
  • Bausch + Lomb is planning a long-term clinical trial to evaluate a new B-vitamin complex formulation.
  • PreserVision AREDS3 eye vitamins, enhanced with B vitamins, are now available in the U.S. and expected to be widely available by June 2026.

The big picture

Bausch + Lomb's move to integrate B vitamins into its PreserVision line reflects a broader trend in the eye health market towards preventative and nutritional interventions for age-related conditions. The company is capitalizing on growing consumer interest in natural supplements and personalized healthcare solutions, particularly as the aging population expands. This research provides a potential competitive advantage, but also introduces execution risk associated with clinical trial outcomes and potential regulatory challenges.

What we're watching

Clinical Validation
The success of the planned long-term clinical trial will be crucial in substantiating the efficacy claims and driving adoption of the B-vitamin enhanced PreserVision formula.
Regulatory Scrutiny
Increased focus on nutritional supplement claims may lead to greater regulatory scrutiny of Bausch + Lomb's marketing and labeling practices for PreserVision.
Competitive Response
Other eye health companies will likely respond to Bausch + Lomb’s findings by exploring their own B vitamin formulations, potentially intensifying competition in the nutritional supplement space.

Bausch + Lomb Commits to 2050 Net Zero, Introduces Sustainability Framework

Event summary

  • Bausch + Lomb released its 2025 Sustainability Impact Report, outlining progress and introducing 'The Broader Perspective' sustainability framework.
  • The company reaffirmed its commitment to achieving Net Zero greenhouse gas emissions by 2050.
  • Bausch + Lomb is decreasing power demand for compressed air by 10% at its Rochester, New York site.
  • The company avoided approximately 25 tons of paper waste since 2023 by transitioning to electronic Instructions for Use.

The big picture

Bausch + Lomb's commitment to net zero and circular economy principles reflects growing investor and consumer pressure on healthcare companies to address environmental and social impact. The introduction of 'The Broader Perspective' framework signals a move towards more formalized ESG governance, but the company's ability to translate these commitments into measurable results will be crucial for maintaining stakeholder trust and potentially attracting impact-focused capital.

What we're watching

Scope 3 Emissions
Developing a Scope 3 emissions inventory is a complex undertaking; the quality and granularity of the data will be critical to demonstrating genuine progress toward net zero and avoiding accusations of greenwashing.
Extended Producer Responsibility
The report highlights responsiveness to Extended Producer Responsibility (EPR) requirements; increased regulatory scrutiny and potential liabilities related to packaging waste will likely continue to shape Bausch + Lomb's product design and supply chain strategies.
Supplier Risk
With over 90% of suppliers registered in the Vendor Risk Management program, Bausch + Lomb's ability to enforce sustainability standards across its supply chain will be a key determinant of its overall ESG performance.

Bausch + Lomb Recycles Over 725,000 Pounds of Eye Care Waste

Event summary

  • Bausch + Lomb's ONE by ONE Recycling program has collected 724,922 pounds (119,715,074 units) of contact lens and eye care materials in the U.S. as of April 6, 2026.
  • The program, a collaboration with TerraCycle, prevents an estimated 6-10 metric tons of contact lenses from entering wastewater annually.
  • For every 10-pound shipment from participating practices, Bausch + Lomb donates $1 per pound to Optometry Giving Sight.
  • The Canadian 'Every Contact Counts' program has recycled 78,269 pounds of materials since 2019.

The big picture

Bausch + Lomb's recycling program addresses a growing consumer and regulatory concern regarding plastic waste in the eye care industry. The initiative, while relatively small in the context of Bausch + Lomb's overall revenue, positions the company as a leader in sustainable practices within a sector increasingly pressured to reduce its environmental footprint. The program's reliance on third-party partnerships (TerraCycle, Optometry Giving Sight) highlights the complexity of building circular economy solutions in specialized product categories.

What we're watching

Program Scalability
The program's reliance on participating eye care practices suggests scalability will depend on Bausch + Lomb's ability to incentivize broader adoption and manage logistics.
Regulatory Pressure
Increasing regulatory scrutiny of single-use plastics and microplastics could accelerate the need for industry-wide recycling solutions, potentially creating both opportunities and competitive pressures for Bausch + Lomb.
Cost Analysis
While the charitable donations create goodwill, the long-term financial viability of the program hinges on optimizing recycling costs and exploring potential revenue streams from recycled materials.

Bausch + Lomb Advances Vitrectomy Tech with FDA Clearance

Event summary

  • Bausch + Lomb received FDA 510(k) clearance for the Bi-Blade+ dual-port vitrectomy cutter.
  • The Bi-Blade+ cutter increases cutting speed to 25,000 cuts per minute from the previous 15,000.
  • The clearance also includes an Adaptive Fluidics update for the Stellaris Elite Vision Enhancement System.
  • Adaptive Fluidics reduces average infusion pressure by 62% compared to surgeries without it.
  • The combined technologies aim to improve IOP stability and surgical efficiency.

The big picture

Bausch + Lomb's advancement in vitrectomy technology underscores the ongoing trend of automation and precision in surgical procedures. The increased cutting speed and Adaptive Fluidics represent a direct response to the demand for more efficient and less invasive surgical techniques, which is particularly important given the aging global population and rising prevalence of age-related eye diseases. This innovation strengthens Bausch + Lomb's position in a competitive market, but also creates pressure to continually innovate.

What we're watching

Adoption Rate
The speed at which retinal surgeons adopt Bi-Blade+ will determine the initial impact on Bausch + Lomb’s surgical revenue, particularly given the existing Bi-Blade user base.
Competitive Response
Competitors in the surgical ophthalmology space will likely accelerate their own innovation efforts to counter Bausch + Lomb’s enhanced offering, potentially leading to a price war or feature escalation.
Clinical Validation
Long-term clinical data demonstrating the sustained benefits of the combined technologies on patient outcomes will be crucial for securing broader adoption and justifying premium pricing.

Bausch + Lomb Expands European IOL Portfolio with enVista Envy Launch

Event summary

  • Bausch + Lomb launched the preloaded enVista Envy intraocular lens (IOL) in Europe on April 7, 2026.
  • The enVista Envy IOL demonstrated an 86.1% patient satisfaction rate regarding dysphotopsia in a U.S. clinical trial.
  • A Canadian study showed 95.4% of patients reported little to no difficulty viewing close objects with the Envy IOL.
  • The launch marks Bausch + Lomb’s second full range of vision premium IOL offering in Europe, alongside LuxLife.
  • The Envy IOL utilizes the new EyeGility delivery system, a first for Bausch + Lomb IOLs.

The big picture

Bausch + Lomb's expansion into the European market for premium IOLs reflects the growing demand for advanced vision correction procedures globally. The introduction of enVista Envy, coupled with LuxLife, positions the company to capture a larger share of this lucrative market segment, which is increasingly driven by patient preference for minimally invasive procedures and improved visual outcomes. The company's focus on dysphotopsia mitigation is a strategic response to a key patient concern in premium IOL adoption.

What we're watching

Market Adoption
The success of enVista Envy in Europe will depend on surgeon adoption and patient demand, which may be influenced by competitor offerings like LuxLife.
Clinical Data
Continued monitoring of long-term clinical outcomes in European patients will be crucial to validate the initial U.S. and Canadian trial results and support reimbursement claims.
Delivery System
The performance and reliability of the EyeGility delivery system will be a key factor in surgeon satisfaction and overall adoption of the enVista Envy IOL.

Bausch + Lomb Showcases Data, Signals Ophthalmology Strategy Shift

Event summary

  • Bausch + Lomb will present 45 scientific data presentations and posters at the ASCRS annual meeting in Washington, D.C., April 10-13, 2026.
  • The presentations will focus on Bausch + Lomb's portfolio, including ELIOS MIGS, enVista IOLs, MIEBO, ScoutPro, Stellaris Elite, TENEO laser platform, and XIIDRA.
  • The company is hosting events including a session on ophthalmology strategics and a debate on the future of communication in ophthalmology.
  • The press release highlights real-world data and patient outcomes across multiple product lines, suggesting a focus on demonstrating clinical value.

The big picture

Bausch + Lomb’s presentation at ASCRS signals a move beyond product promotion to a data-driven approach, emphasizing real-world evidence to bolster its market position. The inclusion of a session on ophthalmology strategics indicates a heightened awareness of industry consolidation and competitive pressures. This focus on clinical data and strategic positioning is crucial for maintaining market share in the increasingly competitive global eye health market, which is projected to reach $45 billion by 2030.

What we're watching

Market Positioning
Bausch + Lomb's emphasis on real-world data suggests a strategic shift towards demonstrating clinical efficacy and value to differentiate from competitors in a crowded market.
Regulatory Scrutiny
Increased focus on patient-reported outcomes and safety data may reflect heightened regulatory scrutiny and a need to proactively address potential concerns.
Competitive Landscape
The discussions around ophthalmology strategics and communication suggest Bausch + Lomb is actively monitoring and responding to evolving competitive dynamics within the eye care market.

Bausch + Lomb Schedules Q1 2026 Earnings Release

Event summary

  • Bausch + Lomb will release its first-quarter 2026 financial results on April 29, 2026.
  • A conference call and live webcast are scheduled for 8:00 AM ET on the same day.
  • Materials will be available on the Investor Relations section of the Bausch + Lomb website prior to the call.
  • The conference call dial-in numbers and webcast link are provided for North America and international participants.

The big picture

The upcoming earnings release provides a crucial data point for assessing Bausch + Lomb’s performance as a standalone entity. The company operates within a large and fragmented global eye health market, facing both organic growth opportunities and competitive pressures. Investor focus will be on the sustainability of recent growth and the execution of its strategic initiatives.

What we're watching

Market Trends
The company's performance will reflect ongoing shifts in consumer preferences towards vision correction and the impact of telehealth on eye care services.
Competitive Landscape
The results will reveal how Bausch + Lomb is navigating increased competition from both established players and emerging direct-to-consumer brands in the eye health market.
Integration Risk
The company's ability to achieve synergies and operational efficiencies following its separation from Bausch Health will be a key indicator of long-term value creation.

Bausch + Lomb ELIOS Glaucoma Data Bolsters US Market Entry Hopes

Event summary

  • Bausch + Lomb released positive 24-month data from a U.S. clinical trial for its ELIOS glaucoma treatment system.
  • The trial, involving 318 patients, demonstrated a 76% achievement of at least a 20% reduction in IOP and an average IOP reduction of 7.4 mmHg.
  • 82% of patients were medication-free at 23 months following the ELIOS procedure.
  • The ELIOS system, already CE marked in Europe, uses excimer laser technology for an implant-free glaucoma treatment.

The big picture

The ELIOS system represents Bausch + Lomb's strategic push into the US minimally invasive glaucoma surgery (MIGS) market, which has seen significant growth in Europe. The positive trial data provides a strong foundation for FDA approval, but the company faces competition from established players and the need to educate US clinicians on the benefits of this implant-free laser technology. Success hinges on navigating the regulatory process and driving adoption among specialists.

What we're watching

Regulatory Approval
The FDA review process will be critical; a protracted or negative review could significantly delay US market entry and impact investor sentiment.
Adoption Rate
The speed at which ophthalmologists and cataract specialists adopt the ELIOS procedure in the US will determine its commercial success, particularly given existing MIGS alternatives.
Competitive Landscape
Bausch + Lomb will need to demonstrate a clear advantage over existing minimally invasive glaucoma surgery (MIGS) options to gain meaningful market share.

Bausch + Lomb to Detail Pipeline with Investor Webinar

Event summary

  • Bausch + Lomb will host an R&D “Teach-in” webinar on March 23, 2026, at 1:30 p.m. ET.
  • The webinar will focus on two glaucoma assets: BL1107 (medication) and ELIOS™ (minimally invasive surgery approach).
  • ELIOS™ is already commercialized in Europe and slated for a U.S. launch in 2H 2026.
  • Key executives including CEO Brent Saunders and R&D Chief Yehia Hashad will participate.
  • The webinar is part of Wells Fargo’s Innovation Spotlight series.

The big picture

Bausch + Lomb’s webinar signals a renewed emphasis on showcasing its R&D pipeline following the November 2025 unveiling. The company is attempting to build investor confidence in its innovation engine, which is crucial for justifying its valuation and navigating a competitive landscape in the eye health market. The inclusion of senior leadership underscores the strategic importance of these pipeline assets to the company’s future growth.

What we're watching

Regulatory Approval
The success of ELIOS™ hinges on a timely and favorable U.S. regulatory review, given the existing European commercialization and the stated launch timeline.
Clinical Adoption
How quickly physicians adopt ELIOS™ will determine its market penetration and impact Bausch + Lomb’s revenue projections, particularly given its implant-free approach.
Pipeline Risk
The focus on BL1107, a first-in-class glaucoma medication, highlights the inherent risk associated with novel therapies and the potential for clinical trial setbacks.

Bausch + Lomb Posts Strong 2025, Guides to Continued Growth Amid Margin Expansion

Event summary

  • Bausch + Lomb reported $1.405 billion in fourth-quarter 2025 revenue, a 10% increase year-over-year, and $5.101 billion for the full year, up 6%.
  • Dry eye product MIEBO generated $112 million in fourth-quarter sales, contributing to a $1.1 billion portfolio revenue for the year.
  • Premium IOLs saw a 20% revenue growth in the fourth quarter, with the enVista platform returning to 2025 Q1 levels.
  • The company is guiding for full-year 2026 revenue between $5.375 billion and $5.475 billion, representing 5-7% constant currency growth.

The big picture

Bausch + Lomb's results demonstrate a renewed focus on operational efficiency and product portfolio optimization following its separation from Bausch Health. The company's success hinges on capitalizing on the growing demand for eye care solutions, particularly in the dry eye and premium IOL segments, while navigating potential regulatory hurdles and competitive pressures within the $150 billion global eye health market. The emphasis on margin expansion signals a shift towards a more disciplined financial strategy.

What we're watching

Margin Sustainability
The company's focus on margin expansion is a key driver of future profitability, but sustained performance will depend on managing input costs and maintaining pricing power in a competitive market.
Clinical Trials
The progress and eventual success of ongoing clinical trials for glaucoma (BL1107), dry eye disease, and ocular surface pain will significantly impact Bausch + Lomb’s long-term growth prospects.
Recall Impact
The voluntary recall of certain enVista IOL products continues to impact the surgical segment, and the pace of recovery will be crucial to monitor.

Bausch + Lomb to Report FY25 Results Amidst Evolving Eye Health Landscape

Event summary

  • Bausch + Lomb Corporation will release its fourth-quarter and full-year 2025 financial results on February 18, 2026.
  • A conference call and live webcast are scheduled for 8:00 a.m. ET on the same day.
  • Materials will be available on the Investor Relations section of the company's website prior to the call.
  • The company is listed on both the New York Stock Exchange (NYSE) and the Toronto Stock Exchange (TSX) under the ticker symbol BLCO.

The big picture

Bausch + Lomb's upcoming earnings release provides a crucial data point for assessing the company's performance in a rapidly evolving eye health market. The company's scale, with a broad portfolio spanning contact lenses, surgical devices, and pharmaceuticals, positions it as a significant player, but also exposes it to diverse market pressures and integration challenges. Investor focus will be on whether the company can sustain growth and profitability amidst these complexities.

What we're watching

Market Dynamics
The company's performance will reflect broader trends in the eye health market, including increasing demand for vision correction and the impact of telehealth on distribution channels.
Competitive Pressure
The results will reveal how Bausch + Lomb is navigating intensifying competition from both established players and emerging technologies in the eye care space.
Integration Risk
The company's ability to effectively integrate acquired assets and realize synergies will be a key determinant of its long-term financial health.

Bausch + Lomb Funds Glaucoma Research Amid Rising Prevalence

Event summary

  • Bausch + Lomb is launching its fifth annual fundraising challenge with the Glaucoma Research Foundation (GRF) in January.
  • Bausch + Lomb will match dollar-for-dollar donations to GRF, up to a maximum of $20,000.
  • The company is also sponsoring The Glaucoma Foundation’s (TGF) social media campaign to raise awareness.
  • Approximately four million people in the U.S. are affected by glaucoma, a number expected to increase with an aging population.
  • GRF has invested over $90 million in glaucoma research since 1978.

The big picture

Bausch + Lomb's continued investment in glaucoma research and awareness aligns with the broader trend of pharmaceutical companies expanding their corporate social responsibility efforts. This partnership strategy serves to bolster brand reputation and potentially influence patient behavior, which can drive demand for their products. The $20,000 matching commitment, while relatively small in the context of Bausch + Lomb’s overall revenue, signals a sustained commitment to the cause.

What we're watching

Market Dynamics
The increasing prevalence of glaucoma, driven by an aging population, will likely intensify competition among eye health companies for market share and innovation in treatment and diagnostics.
Partnership Risk
The reliance on external organizations like GRF and TGF for awareness and fundraising introduces a degree of operational risk; changes in their leadership or strategic direction could impact Bausch + Lomb's initiatives.
Regulatory Scrutiny
As Bausch + Lomb expands its CSR initiatives and engages in public health campaigns, the company may face increased scrutiny regarding transparency and potential conflicts of interest.

Bausch + Lomb Secures $2.8 Billion Refinancing, Extends Debt Maturity

Event summary

  • Bausch + Lomb completed a refinancing of $2.802 billion in outstanding Term B loans.
  • The refinancing involves a fourth amendment to the existing credit agreement, creating 'Replacement Term Loans'.
  • The new loans extend the maturity date from September 29, 2028, to January 15, 2031.
  • The applicable margin on the Replacement Term Loans has been reduced by 0.25% to 0.50% compared to previous loans.
  • The amortization rate for the Replacement Term Loans is 1.00% per annum, with the first installment due June 30, 2026.

The big picture

This refinancing provides Bausch + Lomb with a more manageable debt profile and increased runway, but it doesn't fundamentally alter the company's high-leverage position. The deal reflects ongoing pressure on companies in the healthcare sector to optimize capital structures amidst rising interest rates and economic uncertainty. The extension of the maturity date allows management to focus on operational improvements and potential strategic acquisitions, but also increases scrutiny on their ability to service the debt.

What we're watching

Cost of Capital
The margin reduction suggests Bausch + Lomb was able to negotiate favorable terms, but the sustainability of these rates will depend on broader interest rate trends and the company's performance.
Debt Burden
While the refinancing extends maturity, the substantial debt load remains a key factor in Bausch + Lomb’s financial flexibility and ability to pursue strategic initiatives.
Financial Performance
The company’s ability to meet the new amortization schedule will be directly tied to its operational performance and cash flow generation in the coming years.

Bausch + Lomb Executives to Address J.P. Morgan Healthcare Conference

Event summary

  • Bausch + Lomb Chairman and CEO Brent Saunders, CFO Sam Eldessouky, and CMO Yehia Hashad will present at the 44th Annual J.P. Morgan Healthcare Conference.
  • The presentation is scheduled for January 12, 2026, at 1:30 PM PT.
  • A live webcast and archive will be available on the company's investor relations website.
  • The conference is a significant gathering of healthcare investors and industry leaders.

The big picture

Participation in the J.P. Morgan Healthcare Conference signals Bausch + Lomb's continued focus on investor relations and transparency following its separation from Bausch Health. The presence of the CEO, CFO, and CMO suggests a comprehensive briefing intended to address key areas of investor interest, including financial performance, R&D progress, and strategic direction. This event is a key touchpoint for managing expectations and reinforcing the company's value proposition within a competitive landscape.

What we're watching

Financial Outlook
The presentation will likely be scrutinized for any revised guidance or commentary on the company's financial performance given recent market volatility and macroeconomic pressures.
R&D Pipeline
Investor attention will be focused on Yehia Hashad’s discussion of the R&D pipeline, particularly the progress and potential commercialization timelines for key products.
Strategic Direction
The conference provides an opportunity for Saunders to articulate the company's long-term strategic priorities and address any concerns regarding integration challenges or competitive pressures within the eye health market.
CID: 270